Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from FDA

The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Manufacturing Bottlenecks Hit Launch Of Talis' FDA-Approved COVID-19 Test

Talis Biomedical Corp (NASDAQ: TLIS) said that it had

Benzinga

Pfizer-BioNTech Seek FDA Approval For Second COVID-19 Booster In Elderly Population

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) filed an application with the

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer asks FDA to clear another booster for older adults

Pfizer Inc. said it has asked U.S. regulators for clearance of an additional COVID-19 booster shot for seniors, in a bid to protect vulnerable adults as immunity provided by the first three doses wanes.

Tribune News Service

FDA Recommends At Least 15 years Of Follow-Up For Genome Editing Product Trials

The FDA has outlined new draft guidance on what should be submitted in a clinical trial application and potentially concerning safety issues to track the genome editing products.

Benzinga

Smart For Life Agrees To Acquire Vitamin & Supplement Company Ceautamed For Undisclosed Sum

Smart For Life Inc (NASDAQ:SMFL) has agreed to acquire the vitamin and supplement company Ceautamed Worldwide LLC and its affiliates, Wellness Watchers Global LLC and Greens First Female LLC. The financial terms of the transaction were not disclosed. Ceautamed, based in Florida, is principally engaged in the development and distribution of nutritional products, including antioxidant…

Benzinga

Psyched: Albert Labs Goes Public, Ex-Moderna Executive Joins MAPS, Novamind and Usona Join For Phase 2 Psilocybin Trial

A new company has entered the public psychedelic markets, with an alternative drug-to-market approach. Using Real World Evidence trials, Albert Labs is expecting to legally provide psilocybin to patients in the UK much earlier than companies working with to get FDA approval.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

FDA Issues To Class I Recall To Baxter's Spectrum Infusion Pump

In December 2021, Baxter International Inc (NYSE: BAX) issued an urgent safety communication about an issue with some of its Spectrum infusion pumps.

Benzinga

Solid Biosciences Posts Two-Year Efficacy, Safety Data From Duchenne Gene Therapy Trial

Solid Biosciences Inc (NASDAQ:SLDB) has reported two-year interim efficacy and safety data from the first three patients treated with SGT-001 in the high dose (2E14 vg/kg) cohort as part of IGNITE DMD. Results suggest durable benefit 24-months post-administration of SGT-001 compared to natural history, consistent with results reported at the 12-month and 18-month…

Benzinga

Immunoprecise, Elektrofi To Pursue Low-Volume Injectable Formulation Of IPA's COVID-19 Antibody Cocktail

Elektrofi and Immunoprecise Antibodies Ltd (NASDAQ:IPA) have collaborated to explore a high-concentration formulation of IPA's COVID-19 antibody cocktail, PolyTope TATX-03. The collaboration aims to generate an IND-enabling data package for the FDA for an alternatively formulated version of TATX-03, named TATX-03E, that could be easily self-administered in a non-healthcare setting. The parties anticipate formulating TATX-03E…

Benzinga

FDA Extends Decision Date For Incyte's Ruxolitinib In Vitiligo Skin Disorder

The FDA has extended the review period for Incyte Corporation's (NASDAQ:INCY) supplemental application for ruxolitinib cream (Opzelura) for vitiligo. The Prescription Drug User Fee Act (PDUFA) action date has been extended by three months to July 18 from April 18. The FDA extended the PDUFA action date to review additional data from the ongoing Phase 3…

Benzinga

Wesana Health One Step Closer To Clinical Trials Of Psilocybin And CBD Based Treatment Of Brain Injury Related MDD

Wesana Health Holdings Inc. (OTCQB:WSNAF) (CSE:WESA) have received a full written response from the Food and Drug Administration regarding their pre-investigational new drug meeting for the novel therapy and proprietary protocol of SANA-013 for the treatment of traumatic brain injury related major depressive disorder.

Benzinga

FDA Declines To Approve AstraZeneca's Asthma Treatment For Chronic Nasal Condition

The FDA has declined to approve AstraZeneca Plc's (NASDAQ:AZN) asthma medicine, Fasenra (benralizumab), to treat chronic rhinosinusitis with nasal polyps, a condition characterized by benign growths that cause pain and stuffiness. The FDA has issued a complete response letter following AstraZeneca's application to extend the use of Fasenra and requested additional clinical data…

Benzinga

Test to Treat: pharmacists say Biden’s major new Covid initiative won’t work

Program to facilitate access to antivirals will have a limited impact because pharmacists are restricted from prescribing the pills

The Guardian - US

Get all your
news in one place.

100’s of premium titles.
One news app.

Chicago Sun-Times

Alzheimer’s patients divided on costly new drug: a ‘magic pill’ or ‘risk I’m willing to take’

Medicare has proposed limiting coverage of Aduhelm. Key groups representing patients and families are pressing to make it more widely available. Among people facing the disease, the outlook is more nuanced.

Benzinga

U.S. Senate Appropriations Committee Directs FDA To Regulate CBD And Study Products On The Market

Under Sec. 741 of Division A(p.120), the U.S. Senate Committee on Appropriations has requested for the U.S.

StockNews.com

4 High-Yield Tobacco Stocks to Add to Your Dividend Portfolio

Stringent FDA regulations imposed on nicotine consumption have hindered the tobacco industry’s growth over the past few years. However, manufacturers have produced various alternatives, like e-cigarettes, vapes, and similar smoking substitutes, which could help the industry grow. So, we think high dividend-yielding tobacco stocks Philip Morris (PM), British American (BTI),…

Benzinga

ACHV: 2021 Results: ORCA-3 Underway, ORCA-V1 Soon to Start

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

FDA Lifts Clinical Hold on Immunome's COVID-19 Candidate IND

The FDA has lifted the clinical hold on Immunome Inc's (NASDAQ:IMNM) Investigational New Drug (IND) application for its antibody cocktail (IMM-BCP-01) to treat COVID-19. Immunome previously announced that the FDA had placed its IND application on clinical hold due to a request for further information related to the preparation and administration of IMM-BCP-01 at clinical sites. …

Benzinga

Surgical Robot Maker Memic Terminates SPAC Merger

Memic Innovative Surgery Ltd has pulled out of a reverse merger deal with MedTech Acquisition Corporation (NASDAQ:MTAC), a special purpose acquisition company (SPAC) focused on medical technology. Last August, Memic announced its merger with MedTech Acquisition Corporation to take the surgical robot public. As of this week, however, the deal is off. Memic is a developer of…

Benzinga

Orphazyme Calls For Court-Mediated Restructuring, Lays Off 50% Workforce

Orphazyme A/S's (NASDAQ:ORPH) board of directors has called for a court-mediated restructuring, prompting the second round of layoffs in less than a year. The in-court restructuring will determine whether any operations can continue if the Company can raise any capital or if it is prudent to sell all or some parts of…

Benzinga

LPCN: 2021 Results

By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT

StockNews.com

Up More Than 175% in 2022, is Kaival Brands Innovations Group Still a Buy?

Shares of Kaival Brands Innovations Group (KAVL) have gained more than 175% in price so far this year, driven primarily by the company’s success in winning a judicial stay of a marketing denial order issued by the U.S. Food and Drug Administration last year. However, considering the company’s lean profit…

Benzinga

HeartBeam, Triple Ring To Co-Develop Telehealth Solution Device For Heart Attack Monitoring

HeartBeam Inc (NASDAQ:BEAT) has signed a professional services agreement with Triple Ring Technologies Inc to assist in the design and development of its Telehealth complete solution 3D vector Electrocardiogram (ECG) collection device for remote heart attack or myocardial infarction (MI) monitoring. The joint partnership is a five-phase expedited device development project scheduled to be completed…

Benzinga

Tiziana Life Shares Rise On Encouraging Data From Intranasal Foralumab In Multiple Sclerosis Patient

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported clinical data in a patient with Secondary Progressive Multiple Sclerosis (SPMS) following six months of treatment with intranasally administered foralumab. In addition to being well-tolerated, both biological and clinical improvements were seen in the patient using Tiziana's immunotherapy technology, which overcame the challenge of delivering foralumab…

1 … 222 223 224 225

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Department of Defense

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.